Daily rifapentine treatment test for latent tuberculosis infection
Part of Infections clinical trials.
This trial studies whether taking rifapentine every day is safe and helps prevent active tuberculosis (TB) in people who have latent TB infection. It aims to find the best way to stop TB from becoming a serious illness later.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have latent TB infection confirmed by a positive TB blood test (IGRA) or TB skin test (TST)
- You must have one risk factor that makes TB more likely to become active (for example recent TB exposure, recent infection, HIV, certain chest X-ray findings, or specific recent immigration/refugee history)
- You must not have active TB disease right now (your team must be confident active TB is ruled out)
- You must be able to take daily rifapentine and agree to the study consent process
- If you are pregnant or could become pregnant, you must meet the trial’s pregnancy and birth-control rules
- You must not have recent TB or TB-prevention medicine use that is too close to enrollment, and you cannot have rifamycin allergies or liver enzyme results above the allowed limit
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a very short (one-month) medicine course to prevent tuberculosis (TB) in students and school staff who have been exposed to someone with active TB. If you have latent TB infection (the germs are in your body but you're not sick), this treatment aims to stop it from turning into active TB disease.
This trial studies whether reminder-based “vDOT” and small economic incentives can help people complete treatment for latent (sleeping) tuberculosis. If you have latent TB and are starting a standard medicine plan, it may help you stay on track and finish safely.
This trial tests a shorter, safer treatment for people with latent TB infection (TB germs in your body but not making you sick). The goal is to prevent you from getting sick with active TB later.
This trial studies whether a rifapentine-based TB regimen can work just as well while shortening treatment time. It’s for people with rifampicin-sensitive, smear-positive lung tuberculosis.
This study tests whether a new medicine called MK-8527, combined with the antibiotic rifampin, can safely treat latent tuberculosis infection (a dormant TB infection that shows no symptoms). You may qualify if you have untreated latent TB but feel well otherwise.
This trial tests if a short course of medication can prevent tuberculosis (TB) in children and teenagers who have been in close contact with someone who has active TB. The goal is to see if this approach can stop them from developing the disease.
Hear when a new Latent Tuberculosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.